Arbutus Biopharma financials
$4.69−3.50%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $179.1M | $1.1M | $529.0K | $10.7M | $1.8M | $1.6M | $1.3M | $1.7M | $1.5M | $2.1M | $4.7M |
| Gross profit | $1.0M | $179.1M | $1.1M | $529.0K | $10.7M | $1.8M | $1.6M | $1.3M | $1.7M | $1.5M | $2.1M | $4.7M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$6.0M | $168.9M | -$5.3M | -$8.7M | $1.5M | -$25.7M | -$13.9M | -$21.4M | -$21.6M | -$19.4M | -$20.7M | -$21.6M |
| Net income | -$5.2M | $169.7M | -$3.8M | -$7.7M | $2.5M | -$24.5M | -$12.5M | -$19.7M | -$19.8M | -$17.9M | -$19.3M | -$20.1M |
| Net margin | −512.0% | 94.7% | −357.4% | −1463.5% | 23.3% | −1390.4% | −796.2% | −1472.5% | −1146.9% | −1166.8% | −900.3% | −431.6% |
| Diluted EPS | $-0.03 | $0.87 | $-0.02 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.11 | $-0.12 |
| EBITDA | -$6.0M | $168.9M | -$5.0M | -$8.6M | $1.7M | -$13.0M | -$13.5M | -$17.5M | -$21.2M | -$19.0M | -$20.4M | -$21.2M |
| Operating cash flow | -$6.0M | -$8.1M | -$4.7M | -$5.8M | -$15.7M | -$13.4M | -$10.3M | -$20.7M | -$14.5M | -$19.3M | -$17.4M | -$21.6M |
| Free cash flow | -$6.0M | -$8.1M | -$4.7M | -$5.8M | -$15.7M | -$13.4M | -$10.4M | -$20.7M | -$14.5M | -$19.4M | -$17.4M | -$21.7M |
| Diluted shares | 197.5M | 195.2M | 191.5M | 191.8M | 192.4M | 190.7M | 189.8M | 189.0M | 188.0M | 175.6M | 168.6M | 167.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $19.2M | $23.7M | $18.0M | $22.4M | $37.4M | $37.1M |
| Short-term investments | $73.5M | $71.5M | $73.5M | $71.3M | $60.7M | $75.6M |
| Total debt | $3.1M | $3.3M | $3.4M | $3.7M | $3.9M | $4.4M |
| Total assets | $274.0M | $277.2M | $94.6M | $97.7M | $103.3M | $117.0M |
| Total liabilities | $15.3M | $17.0M | $18.0M | $20.3M | $20.3M | $37.9M |
| Shareholders' equity | $258.7M | $260.2M | $76.6M | $77.4M | $83.0M | $79.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology